Novo Nordisk hopes to stabilize Wegovy supply in early 2022
Production of obesity drug Wegovy is still expected to experience delays for the rest of 2021, but should, however, be stabilized in early 2022, the pharmaceutical company reports.
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN
Novo Nordisk has significantly increased the production of its weight loss drug Wegovy, which is in high demand, and is now hoping to have stabilized its supply early next year, the company writes in an update on its website.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.